A Special 510(k) needs a predicate you own

“Special,” “Abbreviated,” and “Traditional” never appear in 21 U.S.C. § 360(k) or in 21 CFR Part 807, Subpart E — the statute and the regulation that actually require premarket notification. Every one of those category names is FDA’s own administrative invention, defined in guidance, sorting submissions into three different review processes against the same underlying legal standard: substantial equivalence. A Special 510(k) is the fastest of the three on paper, and the condition that earns it that speed is easy to read past.

What the speed is actually bought with

FDA’s September 2019 guidance, The Special 510(k) Program, targets a 30-day review from receipt by the Document Control Center, against 90 days for a Traditional or Abbreviated submission. That faster clock is not a reward for a small change; it is a function of what FDA does not have to do. The guidance says plainly that the program relies on FDA’s previous review of detailed information already in the submitter’s own prior 510(k) — the device history, the design control records, the risk analysis FDA has already seen once. A reviewer working a Special 510(k) is checking a modification against a file already on hand, not building a predicate comparison from zero.

Which is why the predicate has to be yours

The 2019 guidance is explicit that the pathway covers a manufacturer modifying its own legally marketed device — not a comparable device another company makes and markets. A company citing a competitor’s cleared device as predicate, however close the match, is not eligible for a Special 510(k) on that submission, no matter how minor the proposed change looks sitting next to it. The file the program leans on does not exist, because FDA never built it for anyone else’s device. That submission runs as Traditional, on the 90-day track, regardless of how well-established the comparison testing is.

A Special 510(k) does not get its speed from the size of the change. It gets it from a file FDA already has.

What widened in 2019, and what didn’t

Before the 2019 update, the program excluded any change to intended use or to the device’s fundamental technology outright. The current guidance drops that categorical bar and replaces it with a different test: whether the method used to evaluate the change is well-established, and whether the result can be reviewed in summary or risk-analysis form rather than a full study report. That change widened what kind of modification can qualify — including, now, certain changes to indications for use. It did not touch the ownership condition underneath it. A well-established test method run on someone else’s device still does not make a Special 510(k) available to you.

The practice

Before routing a change toward a Special 510(k), the question worth asking first is not “is this change small enough” but “is the predicate mine.” A manufacturer that acquired a device line through an asset purchase, or that is modifying a device cleared under a different corporate entity before a merger, can find the ownership condition less obvious than it looks: the 510(k) holder of record, not the device’s current factory of origin, is the fact that decides eligibility. FDA Radar’s own 510(k) feed carries K-number, applicant, and decision for exactly that kind of check — who holds the clearance a proposed change would modify. Whether a specific modification and a specific predicate clear the Special 510(k) bar is a determination for the submitter’s own regulatory team, reading the actual device history; this is regulatory intelligence and method, never regulatory advice.